
Raul D. Mitrani MD, FACC, FHRS
Director of Clinical Cardiac Electrophysiology, and Director of the Cardiac Electrophysiology Laboratory at University of Miami, Miller School of Medicine, Miami, FloridaDr Raul Mitrani is Director of Clinical Cardiac Electrophysiology, and Director of the Cardiac Electrophysiology Laboratory at University of Miami, Miller School of Medicine. As an Academic Cardiac Electrophysiologist, Dr Mitrani treats patients with simple and complex cardiac arrhythmias including atrial fibrillation, ventricular tachycardia, supraventricular tachycardia and syncope. He performs the full gamut of cardiac ablation procedures as well as cardiac electrical device implants.
In addition to his clinical responsibilities, Dr Mitrani is actively involved in research and teaching. He has authored or coauthored numerous papers on diverse topics including the role of cardiac stem cells in cardiac arrhythmias, optimal blood pressure control in patients with atrial fibrillation, and others. Recently, he has co-authored chapters and review articles on the topic of Sudden Cardiac Death. He is currently involved in preclinical studies on the effects of mesenchymal stem cells in a post –infarct swine model. He is involved in various NIH-sponsored trials including the CONCERT-HF Trial, a study of Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure (CONCERT-HF; NCT02501811). He also is involved in studies examining the effects of Mesenchymal Stem Cells in patients with nonischemic cardiomyopathy (POSEIDON-DCM -NCT01392625) and ischemic cardiomyopathy (TRIDENT -NCT02013674). He participates in NIH sponsored multicenter trials such as the CABANA Trial, a study to compare catheter ablation versus pharmacologic therapy in patients with atrial fibrillation.
Disclosures
He is currently involved in preclinical studies on the effects of mesenchymal stem cells in a post –infarct swine model. He is involved in various NIH-sponsored trials including the CONCERT-HF Trial, a study of Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure (CONCERT-HF; NCT02501811). He also is involved in studies examining the effects of Mesenchymal Stem Cells in patients with nonischemic cardiomyopathy (POSEIDON-DCM -NCT01392625) and ischemic cardiomyopathy (TRIDENT -NCT02013674). He participates in NIH sponsored multicenter trials such as the CABANA Trial, a study to compare catheter ablation versus pharmacologic therapy in patients with atrial fibrillation.Recent Contributions to PracticeUpdate:
- Prediction of Sudden Cardiac Death Manifesting With Documented Ventricular Fibrillation or Pulseless Ventricular Tachycardia
- Novel ECG Risk Score Promising for Predicting Risk of Sudden Cardiac Death
- Left Ventricular Geometry Predicts Risk of Sudden Cardiac Arrest in Patients With Severely Reduced Ejection Fraction